Immediate Stool Testing and Evaluation for Alternative Pathogens or Post-Infectious Complications
This patient requires immediate repeat stool testing for persistent/chronic infection (particularly Giardia, Cryptosporidium, and C. difficile), blood work to exclude systemic disease, and consideration of post-infectious IBS or treatment failure—not simply continuation of azithromycin. The combination of persistent diarrhea beyond 14 days with constitutional symptoms (nighttime chills) at age 52 demands exclusion of chronic infection, systemic illness, or complications rather than assuming adequate treatment 1, 2.
Critical Next Steps in Evaluation
Stool Testing Priority
- Test three fresh stool samples for ova, cysts, and parasites with specific focus on Giardia (60-90% sensitivity) or use Giardia stool ELISA (92% sensitivity, 98% specificity) 1
- Mandatory C. difficile testing using two-stage approach: First, glutamate dehydrogenase EIA or PCR to detect organism presence; second, toxin EIA to confirm active toxin production 1. This is critical because azithromycin itself can trigger C. difficile infection 3
- Test for Cryptosporidium and other protozoan infections that commonly cause persistent diarrhea in immunocompetent hosts 1, 4
Blood Work Required
- Complete blood count, ferritin, tissue transglutaminase/EMA (coeliac screening), thyroid function tests 1
- HIV testing is mandatory given persistent symptoms and nighttime chills suggesting possible immunocompromise 1
- Consider inflammatory markers
Faecal Calprotectin
- Obtain faecal calprotectin to distinguish inflammatory bowel disease from functional causes 1
Why Azithromycin May Have Failed
Resistance Considerations
Campylobacter resistance to macrolides (including azithromycin) is increasing globally and represents a major public health problem 5. Recent data shows:
- Over 94.8% of dual-resistant (ciprofloxacin + azithromycin) Campylobacter isolates are also resistant to clindamycin 6
- No clear oral alternative exists for macrolide-resistant Campylobacter, though amoxicillin-clavulanate shows promise (only 2.6% resistance) 6
- Carbapenems maintain universal susceptibility but require IV administration 6
Alternative Explanations for Persistent Symptoms
Post-infectious IBS is well-recognized after Campylobacter infection and can mimic ongoing infection 1. However, nighttime chills suggest active pathology rather than functional disease.
C. difficile superinfection occurs in 25% of patients in clinical trials and can develop after any antibiotic, including azithromycin 1, 3. The FDA label explicitly warns of C. difficile-associated diarrhea with azithromycin 3.
Management Algorithm
If Repeat Testing is Positive:
- Giardia: Metronidazole or tinidazole (short course) 1
- C. difficile with positive toxin: Discontinue azithromycin; initiate C. difficile-directed therapy 1, 3
- Cryptosporidium: Supportive care in immunocompetent; investigate for immunodeficiency if persistent 1
- Resistant Campylobacter (if still positive): Consider amoxicillin-clavulanate or IV carbapenem if severe 6
If Testing is Negative:
- Consider empiric trial of metronidazole for presumed Giardia (given test sensitivity limitations) 1
- Evaluate for bile acid diarrhea, microscopic colitis, or other organic causes
- Do NOT continue empiric antibiotics for persistent watery diarrhea >14 days without identified pathogen 2
Critical Pitfalls to Avoid
Do not assume adequate treatment without microbiologic confirmation of clearance. The absence of repeat stool testing is a major gap in this case 2.
Do not ignore constitutional symptoms. Nighttime chills in a 52-year-old with chronic diarrhea warrant exclusion of systemic infection, bacteremia (rare but described with Campylobacter in patients with comorbidities 7), or underlying immunocompromise 1.
Avoid PCR-only diagnosis of C. difficile without toxin confirmation, as this can lead to overtreatment of colonization rather than active infection 1.
Do not empirically retreat with azithromycin without documented susceptibility, given rising macrolide resistance 5, 6.